Zepbound Cost Without Insurance in 2026: Cash Prices Explained
Without insurance, Zepbound costs $299 to $449 per month through Lilly's self-pay program, depending on dose. The $449 tier for higher doses requires refills within 45 days; Lilly's own pages give conflicting regular prices if you miss it, from $499 up to $1,049.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Without insurance, you will most likely pay between $299 and $449 per month for Zepbound in 2026, if you buy it through Lilly’s self-pay program with a valid prescription [2][5][6]. The exact number depends on your dose and on one condition: the $449 price for the four highest doses only holds if each refill purchase is completed within 45 days of the previous delivery. Miss that window and higher regular prices take over — and Lilly’s own pages disagree on exactly what those are, listing figures from $499 up to $1,049 depending on the page [2][5][6].
Those self-pay prices are far below the list price. Lilly’s consumer pricing page lists Zepbound at $499 to $1,086.37 per fill before discounts, and CNBC has reported the list price as roughly $1,086 per month [1][4]. The self-pay prices are set by Lilly itself and are available to anyone with a valid, on-label prescription, regardless of insurance status [7][3].
What is the cash price of Zepbound by dose?
Lilly sells Zepbound directly to cash-paying patients at fixed monthly prices through LillyDirect. A “month” is defined as 28 days, which equals either 4 single-dose vials or 1 single-patient-use KwikPen [1][5].
| Dose | Self-pay price per month | Price if the 45-day refill window is missed |
|---|---|---|
| 2.5 mg | $299 [2][5][6][8] | $299 (no 45-day condition) [2][5] |
| 5 mg | $399 [2][5][6] | $399 (no 45-day condition) [2][5] |
| 7.5 mg | $449 [2][5][6] | $499 [2][5] |
| 10 mg | $449 [2][5][6] | $699 [2][5] |
| 12.5 mg | $449 [2][5][6] | $699 [2][5] |
| 15 mg | $449 [2][5][6] | $699 [2][5] |
The $449 figure for the 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses is not a standing list price. It is the price under the Zepbound Self Pay Journey Program, a purchase offer that Lilly applies automatically on the first purchase of those strengths, beginning February 23, 2026 [5]. The 2.5 mg and 5 mg prices of $299 and $399 are not subject to the 45-day condition [2][5].
Note that Lilly’s own pages disagree on what the “regular” prices are for the higher doses when the program terms are not met. The current LillyDirect footnote lists them as $499 for 7.5 mg and $699 each for 10 mg, 12.5 mg, and 15 mg [2][5]. A December 1, 2025 Lilly press release footnote listed the non-Journey regular prices as $599 for 7.5 mg, $699 for 10 mg, $849 for 12.5 mg, and $1,049 for 15 mg [6]. The two footnotes differ on the 7.5 mg, 12.5 mg, and 15 mg doses. Separately, Lilly’s pricing information page lists its direct-to-patient prices as $299, $399, $499, $699, $699, and $699 by dose [1].
What is the difference between the list price and the cash price?
The list price, also called the wholesale acquisition cost or WAC, is the price at which Lilly sells the product to wholesalers. Lilly’s pricing page states the list price of Zepbound is $499 to $1,086.37 per fill, with WAC data from AnalySource accessed on January 1, 2026 [1]. CNBC has described the Zepbound list price as roughly $1,086 per month [4].
What a patient actually pays depends on the out-of-pocket costs set by an insurer, pharmacy charges, and any discounts or financial assistance available [1]. The cash price is different: it is the direct-to-patient price at which Lilly sells the product straight to patients who pay out of pocket, and it is not the WAC [1].
What is the 45-day refill rule, and what happens if you miss it?
The Zepbound Self Pay Journey Program purchase offer gives you the $449 price on the 7.5 mg, 10 mg, 12.5 mg, and 15 mg single-dose vials or KwikPens. The offer is applied automatically on the first purchase of one of those strengths, beginning February 23, 2026 [5].
To keep the offer, the program requires that each refill purchase be completed within 45 days of the delivery or received date of the previous Zepbound prescription [5][2]. If a refill purchase is completed more than 45 days after that delivery date, the purchase offer does not apply, and the regular price takes over [5].
Because a month of treatment is a 28-day supply, a fill delivered on day one leaves roughly 17 days before the 45-day deadline runs out [5].
If the window is missed, the regular prices in the current LillyDirect footnote apply — $499 for 7.5 mg and $699 each for 10 mg, 12.5 mg, and 15 mg [2][5]. As noted above, a December 2025 Lilly press release footnote lists different figures for three of those doses [6].
Vial, KwikPen, or single-dose pen — which one gets the cash price?
Zepbound comes in three presentations, and the one your prescriber writes for determines whether the self-pay price applies at all.
The single-dose vial is a 4-count pack of 0.5 mL vials, sold exclusively through LillyDirect, self-pay only, with free delivery and pickup available. A needle and syringe purchase is required [2].
The KwikPen for single-patient use is a 2.4 mL device that delivers 0.6 mL per dose, so its 4 doses equal one month of treatment in a single device [1][5][8]. It accepts select insurance and self-pay, comes with free delivery, and supports pickup. A pen needle purchase is required [2]. The FDA approved the label expansion for the four-dose KwikPen, which Lilly announced on February 23, 2026 [8].
The single-dose pen is the insurance-billed presentation. It accepts insurance, includes a needle in each pen, and carries the $25-per-month price tier for eligible commercially insured patients with coverage [2].
The self-pay price is the same for the vial and the KwikPen at every dose [8][2]. All three presentations are HSA/FSA eligible, though eligibility varies by plan [2].
Where can you fill a Zepbound prescription at the self-pay price?
On March 16, 2026, Lilly announced that self-pay pricing on the KwikPen would be available at LillyDirect and major pharmacies nationwide, starting at $299 per month for the 2.5 mg dose [3]. The KwikPen Self-Pay Savings Card, at zepbound.lilly.com/savings, is available to all patients, including those without insurance coverage, and adults with a valid, on-label KwikPen prescription can use it to access the same self-pay prices offered through LillyDirect [3]. The card applies only to the KwikPen, not to single-dose vials or the single-dose pen [3].
Through LillyDirect, the savings are applied automatically. At a retail pharmacy, the self-pay savings card is required to get those prices [5][2].
For vials, Walmart became the first retail pickup option for LillyDirect self-pay prescriptions. The collaboration was announced on October 29, 2025, with availability at nearly 4,600 Walmart pharmacies nationwide by mid-November 2025 [7]. Prescriptions are routed through the prescriber’s electronic health record system, and at checkout there is a choice of free home delivery from LillyDirect or local pickup at Walmart, at the same price either way [7]. LillyDirect is listed as a pharmacy option in all major EHR systems [3].
Who qualifies for the KwikPen Self-Pay Savings Card?
The card’s eligibility rules require that you have been prescribed the Zepbound single-patient-use KwikPen for an approved use consistent with FDA-approved product labeling; that you are a self-paying (cash) patient who will not seek or accept reimbursement from any third-party payer; that you are a resident of the United States or Puerto Rico; and that you are 18 or older [5].
The card terms let you pay as low as $299 for a 1-month fill of the 2.5 mg KwikPen (maximum monthly savings up to $215), $399 for the 5 mg KwikPen (up to $115), $449 for the 7.5 mg KwikPen (up to $65), and $449 for the 10 mg, 12.5 mg, or 15 mg KwikPen (up to $271) [5].
Spending with the card cannot be applied toward any deductible or true out-of-pocket requirements [5]. The program is not insurance, and card eligibility and terms may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason [1][2][5]. Savings are subject to monthly and annual limits [1][2].
Separately, insured commercial patients with coverage for Zepbound may pay as low as $25 for a one- or three-month supply of single-dose pens. Governmental beneficiaries are excluded from that offer [1][5].
Can Medicare or Medicaid patients use these prices?
Governmental beneficiaries are excluded from the $25 single-dose pen savings card [1][5]. However, Lilly’s LillyDirect KwikPen page routes eligible Medicare Part D patients with a Zepbound KwikPen prescription for weight management to the Medicare GLP-1 Bridge program [2].
Under that program, eligible Part D beneficiaries with a weight-management Zepbound prescription may pay no more than $50 per month, with injection supplies sold separately [5]. Certain Medicare Part D plan types are excluded, actual eligibility is based on the Medicare GLP-1 Bridge Clinical Criteria, and the program is not a guarantee of coverage. The CMS page is the reference for details [5].
For Medicaid, Lilly’s pricing page directs patients to the Medicaid state-overviews page to check qualification and copayment information in their state [1]. The self-pay prices themselves are available to anyone with a valid, on-label prescription regardless of insurance status [7][3], but the savings card terms bar seeking reimbursement from any third-party payer, including state or federal healthcare programs [5].
Why do older Zepbound prices you see online look wrong?
Zepbound’s cash prices have changed quickly, so articles and forum posts from even a few months ago can be stale.
Before December 2025, LillyDirect vial prices were $349 per month for the 2.5 mg dose and $499 per month for all other doses [6][7]. On December 1, 2025, Lilly cut the vial cash prices to $299 for 2.5 mg, $399 for 5 mg, and $449 for all other doses [6][4].
That cut followed November 2025 deals between the Trump administration and both Lilly and Novo Nordisk on GLP-1 access and pricing [4]. Lilly’s agreement with the administration centered on lowering the price of a multi-dose pen after FDA approval [4]. On February 23, 2026, the KwikPen launched at the same self-pay prices as the vial, starting at $299 [8].
For comparison, Novo Nordisk in November 2025 cut the cash price of Wegovy and Ozempic to $349 per month from $499, excluding the highest dose of Ozempic, and launched a temporary introductory offer of $199 per month for the first two months on the two lowest doses [4].
How much does a year of Zepbound cost without insurance?
Lilly defines a month as a 28-day supply [1][5]. On that definition, a 365-day year works out to roughly 13 fills — that is simple calendar arithmetic, not a program term or a fill cap.
The price tiers can be multiplied out for budgeting. Thirteen fills all priced at the $449 tier total 13 × $449 = $5,837 [2][5]. A different mix — one fill at the $299 tier, one at the $399 tier, and eleven at the $449 tier — totals $299 + $399 + (11 × $449) = $5,637 [2][5]. These are arithmetic examples on the published price ladder, not a description of what anyone should take: which dose a patient takes and for how long is a prescriber’s decision, and the 2.5 mg dose is for initiation only and is not an approved maintenance dose [2][5][8].
If the 45-day window were missed on every fill at the 10 mg dose, the year would cost 13 × $699 = $9,087 [2][5].
On top of the headline price, pen needles are required for the KwikPen, and needles and syringes for the vial, none of which are included [2]. Taxes and fees may also apply [5].
What about GoodRx, SingleCare, and other discount sites?
The source pages for GoodRx, SingleCare, and TrumpRx could not be retrieved for verification, so no specific coupon dollar figures from those sites can be cited here [10][11][12]. Any numbers quoted from those sites should be checked against the live page.
Two things are clear from the verified sources. First, the savings card terms bar seeking reimbursement from any third-party payer, meaning the cards are used instead of insurance, not alongside it [5]. Second, Lilly’s self-pay prices are set by Lilly, not negotiated by coupon sites, and retail KwikPen cash access runs through Lilly’s own self-pay savings card [3].
What doses and safety warnings come with Zepbound?
Zepbound comes in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses. The 2.5 mg dose is a starting dose and is not an approved maintenance dose [3][5][8]. The recommended maintenance doses for weight reduction are 5 mg, 10 mg, or 15 mg injected subcutaneously once per week; the recommended maintenance doses for obstructive sleep apnea are 10 mg or 15 mg [3][8].
Zepbound is indicated for adults with obesity, or overweight with at least one weight-related medical problem, used with a reduced-calorie diet and increased physical activity. It is also approved for adults with moderate-to-severe OSA and obesity [3][8].
Zepbound carries a boxed warning about the risk of thyroid C-cell tumors. It is contraindicated for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3][6]. It should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist, and its safety and effectiveness in children have not been established [3][8].
The self-pay programs require patients to certify that they have a prescription for an approved use consistent with FDA-approved product labeling, and no prior authorization is needed [5]. Dosing and suitability questions belong with a healthcare provider.
Sources
- Eli Lilly and Company. Zepbound cost information: with or without insurance. Zepbound (tirzepatide) injection.
- Eli Lilly and Company. Authentic Zepbound (tirzepatide) shipped to you. LillyDirect.
- Eli Lilly and Company. Media statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect. March 16, 2026.
- CNBC. Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site. December 1, 2025.
- Eli Lilly and Company. Coverage, affordability, and savings. Zepbound (tirzepatide).
- Eli Lilly and Company. Lilly lowers the price of Zepbound (tirzepatide) single-dose vials. December 1, 2025.
- Walmart. LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound. October 29, 2025.
- Eli Lilly and Company. Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen. February 23, 2026.
- Business Wire. Amazon Pharmacy expands access to Eli Lilly’s Zepbound KwikPen for weight management. March 9, 2026.
- GoodRx. Zepbound 2026 prices, coupons & savings tips.
- SingleCare. Zepbound coupons 2026: up to 80% discount - how much does Zepbound cost?
- TrumpRx. Zepbound vial on TrumpRx.
- Eli Lilly and Company. Savings & insurance options. Zepbound (tirzepatide).
- US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
- US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Patent information.
Frequently asked questions
What is the cheapest legitimate way to buy Zepbound without insurance?
Lilly's own self-pay program is the lowest price documented in the retrievable sources: $299 per month for the 2.5 mg dose, $399 for 5 mg, and $449 for higher doses when refills stay within 45 days, for either the vial or the KwikPen. Discount-site pages could not be verified, so check any coupon price against the live page before buying.
Is the $299 price available at a local pharmacy or only by mail?
Both. On March 16, 2026, Lilly announced KwikPen self-pay pricing at LillyDirect and major pharmacies nationwide, starting at $299 per month for the 2.5 mg dose. At a retail pharmacy the KwikPen Self-Pay Savings Card is required; through LillyDirect the savings apply automatically.
What happens if my refill is later than 45 days?
The $449 Journey Program price no longer applies to the 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses, and regular prices take over: $499 for 7.5 mg and $699 for 10 mg, 12.5 mg, and 15 mg per the current LillyDirect footnote. A December 1, 2025 Lilly press release footnote listed different figures for three of those doses: $599 for 7.5 mg, $849 for 12.5 mg, and $1,049 for 15 mg.
Do the vial and the KwikPen cost the same?
Yes. Patients can access all doses in either the multi-dose KwikPen or single-dose vial at the same self-pay price, starting at $299. The KwikPen requires a pen needle purchase; the vial requires needles and syringes.
Why does the prescription presentation matter for the cash price?
Self-pay pricing applies to the single-dose vial and the KwikPen only. The single-dose pen is the insurance-billed presentation, with a $25-per-month tier for eligible commercially insured patients with coverage, and it is not part of the self-pay program.
Can Medicare or Medicaid patients use the self-pay price or savings card?
Governmental beneficiaries are excluded from the $25 single-dose pen savings card. Eligible Medicare Part D patients with a weight-management prescription may instead access the Medicare GLP-1 Bridge program, paying no more than $50 per month, with injection supplies sold separately.
Do cash payments count toward a deductible or out-of-pocket limit?
No. The savings card terms state that spending with the card cannot be applied toward any deductible or true out-of-pocket requirements, and card users agree not to seek reimbursement from any third-party payer.
What does a full year of Zepbound cost without insurance?
Lilly defines a month as a 28-day supply, so a year works out to roughly 13 fills by simple arithmetic. Thirteen fills at the $449 tier total $5,837; a mix of one $299 fill, one $399 fill, and eleven $449 fills totals $5,637. Missing the 45-day window on every fill at 10 mg would raise the year to $9,087, before needles, taxes, and fees.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.